Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $28.83

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received a consensus recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $28.83.

Several equities research analysts have issued reports on KURA shares. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, StockNews.com raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna Fundamental Investments LLC purchased a new stake in Kura Oncology in the 1st quarter valued at about $507,000. Assenagon Asset Management S.A. increased its position in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the period. Sofinnova Investments Inc. lifted its holdings in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC boosted its position in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the period.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $18.57 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. Kura Oncology has a 1 year low of $8.17 and a 1 year high of $24.17. The firm has a market capitalization of $1.42 billion, a PE ratio of -7.87 and a beta of 0.86. The business’s 50 day moving average price is $18.67 and its 200-day moving average price is $19.99.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.